Alzheimer’s drug donanemab for use in the country's national health service (NHS). The National Institute for Health and Care Excellence (NICE), which sets drug policy for the NHS, issued a draft guidance on Wednesday,

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the company said on Wednesday.

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to be funded by the NHS, according to cost-effectiveness watchdog NICE. GB is the first country in Europe to approve amyloid inhibitor Kisunla (donanemab) and only the third to do so worldwide after the US and Japan.

U.K. regulators will reportedly recommend the NHS not cover Eli Lilly’s (LLY) donanemab for the treatment of early Alzheimer’s disease because it’s too expensive. Read more here.

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too expensive for NHS patients, the Telegraph reported on Tuesday.

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.

A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the watchdog says.

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's disease, the company said on Wednesday. Britain is the third major market where donanemab,